WO2001021194A2 - Method for the therapeutic management of endometriosis and fallopian tube obstruction - Google Patents

Method for the therapeutic management of endometriosis and fallopian tube obstruction Download PDF

Info

Publication number
WO2001021194A2
WO2001021194A2 PCT/EP2000/009212 EP0009212W WO0121194A2 WO 2001021194 A2 WO2001021194 A2 WO 2001021194A2 EP 0009212 W EP0009212 W EP 0009212W WO 0121194 A2 WO0121194 A2 WO 0121194A2
Authority
WO
WIPO (PCT)
Prior art keywords
antagonist
lhrh antagonist
short
induction treatment
administration
Prior art date
Application number
PCT/EP2000/009212
Other languages
French (fr)
Other versions
WO2001021194A3 (en
Inventor
Jürgen Engel
Hilde Riethmüller-Winzen
Ricardo Felberbaum
Klaus Diedrich
Wolfgang Küpker
Original Assignee
Zentaris Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to PL353244A priority Critical patent/PL201898B1/en
Priority to UA2002043346A priority patent/UA73956C2/en
Application filed by Zentaris Ag filed Critical Zentaris Ag
Priority to HU0202741A priority patent/HUP0202741A3/en
Priority to CA002383510A priority patent/CA2383510A1/en
Priority to AU77792/00A priority patent/AU769482B2/en
Priority to EP00967722A priority patent/EP1214086A2/en
Priority to IL14818500A priority patent/IL148185A0/en
Priority to BR0014198-4A priority patent/BR0014198A/en
Priority to JP2001524618A priority patent/JP2003509467A/en
Priority to SK375-2002A priority patent/SK3752002A3/en
Priority to MXPA02002436A priority patent/MXPA02002436A/en
Publication of WO2001021194A2 publication Critical patent/WO2001021194A2/en
Publication of WO2001021194A3 publication Critical patent/WO2001021194A3/en
Priority to NO20021430A priority patent/NO331198B1/en
Priority to BG106584A priority patent/BG66128B1/en
Priority to HK03101215.4A priority patent/HK1049117A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Definitions

  • Endometriosis is one of the most frequently encountered pathologies diagnosed amongst gynecological patients. For example, between 10% and 25% of women presenting with gynecological symptoms in UK and in the USA are affected. Clinical diagnosis is made usually by laparoscopic observation of hemorrhagic or fibrotic foci on the pelvic organs. The ectopic endometrial tissue responds to ovarian hormones undergoing cyclic changes. The cyclical bleeding from the endometric deposit contributes to a local inflammatory reaction. Endometriosis commonly affects women during their childbearing years with an incidence of at least 1 % (see Shaw, R.W. (1993), An Atlas of Endometriosis. The Parthenon Publishing Group).
  • Endometriosis is usually classified into endometriosis (genitalis) interna (adenomyosis), endometriosis genitalis externa and endometriosis extragenitalis.
  • Chronic pelvic pain may occur either in relation to endometriosis or as an independent disease.
  • Fallopian tube obstruction is a relatively common disease and may account to for up to 20 % of cases of tubal infertility (see Winfield, A.C. et al., Apparent cornual occlusion in hysterosalpingography: Reversal by glucagon. AJR Am J Roentgenol 1982; 139: 525 - 527).
  • FTO represents a heterogenous group of underlying pathology, preliminary intrinsic occlusion or extrinsic compression from estrogen-sensitive disorders, such as endometriosis, adenomyosis, endosalpingiosis, and myomata. FTO is frequently diagnosed by hysterosalpingography, besides laparascopy.
  • First choice of treatment comprises laparoscopic removal of endometric lesions. This procedure may be followed by the treatment with Danazol or LHRH agonist (for a period of six months). Women being treated with Danazol might experience gastrointestinal and hepatic disorders as well as severe androgenic side effects.
  • Hodgen teaches such a regimen or dose of GnRH antagonist to achieve a 24 hour serum estradiol level in the range of about 25 to 50 and preferably about 35 to 45 pg/ml.
  • Hodgen does not describe estradiol serum levels oscillating between 50 pg/ml and 75 pg/ml.
  • Hodgen only teaches in the US Patent 5,658,884 a continuous long-term treatment (on a daily or periodic basis, the latter meaning a weekly or monthly administration) but not a short-term induction treatment for only 4 to 12 weeks.
  • Hodgen also does not describe any combination therapy comprising the GnRH antagonist in the treatment of endometrosis. The treatment is only described on monkeys and also includes the performance of a costly and repeated progesterone challenge test to provide an 24 hour average serum estradiol level of 30 to 50 pg/ml.
  • LHRH antagonists exert an immediate onset of hormonal suppression, and therefore benign gynecological tumors, such as uterine fibroids decrease within short time [Human Reproduction 1998, 13 ]
  • the present invention relates to the improvement of the medical treatment of extrauterine proliferation of endometrial tissue, i. e. the administration of LHRH antagonists in patients with clinical symptoms of endometriosis, the improvement consisting of : immediate reduction of ectopic endometrial tissue immediate cessation of symptoms, e.g. severe pain, chronic pelvic pain and dysmenorrhea prevention of any progress of the disease avoidance of hormonal withdrawal symptoms prevention of ovarian cyst formation, demineralization of bones as well as of gastrointestinal or hepatic disorders.
  • the inventive medical therapy can start in the early to mid follicular phase, preferably on cycle day one to three.
  • the estradiol serum concentration levels are kept between 35 pg/ml and 80 pg/ml, preferably between about 45-75 pg/ml, more preferably between about 50-75 pg/ml.
  • the LHRH antagonist is administered only for 4 to 12 weeks (short-term induction treatment), either by daily, weekly or monthly administration.
  • the administration of a contraceptive, a non-steroidal anti-rheumatic, an analgetic, an androgen other than 17-alpha-alkyl substituted testosterone or any combinations thereof is provided according to the present invention.
  • LHRH antagonist therapy is started on menstrual cycle day one to three. Before starting LHRH- antagonist therapy the diagnosis is performed by laparoscopy. In cases of severe pain, LHRH antagonist therapy might be initiated without prior laparascopy.
  • estradiol values are kept in the range of the early follicular phase of 35 to 80 pg/ml, preferably between about 45-75 pg/ml, more preferably between about 50-75 pg/ml without further increase or decrease.
  • No titering of the dosage of the LHRH antagonist e.g. by conducting a costly progesterone challenge test, is necessary.
  • the method of therapeutic management of extrauterine proliferation of endometrial tissue therefore embraces: immediate reduction of ectopic endometrial tissue prevention of any progress of the disease avoidance of hormonal withdrawal symptoms prevention of ovarian cyst formation, demineralization of bones as well as of gastrointestinal or hepatic disorders start of medical therapy on cycle day one to three and maintenance of estradiol levels at values of the early follicular phase throughout the entire duration of treatment by means of administration of a LHRH antagonist wherein the antagonist is preferabely cetrorelix, teverelix, ganirelix, antide or abarelix.
  • the antagonist can also be the LHRH antagonist D-63153 (Ac-D-Nal-D-pCI-Phe-D-Pal-Ser-N-Me-Tyr-D- Hci-Nle-Arg-Pro-D-Ala-NH2) as described in the German Patent Application No. 199 11 771.3 filed on March 11 , 1999.
  • the LHRH antagonist may be given for 4 to 12 weeks in a weekly dose of 3 to 10 mg per week or for 4 to 12 weeks in a daily dose of 0.25 mg to 0.5 mg/day.
  • the LHRH antagonist is given for 4 to 12 weeks and the treatment is repeated two or three times a year, whereby a repeated treatment does not following directly after a short-term induction treatment.
  • a period of time of weeks or months, where no LHRH antagonist is administered is between the end of the short-term induction treatment and the start of the repeat treatment.
  • the figure 1 shows the continuous estradiol suppression to values of the early follicular phase (range of 35 pg/ml to 80 pg/ml, preferably between 45-75 pg/ml, more preferably between about 50-75 pg/ml) obtained in patients with endometriosis by a weekly dose of 3 mg of Cetrorelix (LHRH antagonist) for 8 weeks. Immediate and continuous suppression of estradiol levels is obtained without any signs of estradiol withdrawal symptoms and without proliferation of the endometrium at the end of treatment.
  • LHRH antagonist Cetrorelix
  • Fig. 2 shows estradiol serum levels after administration of cetrorelix at a weekly dose of 1 mg resp. 3 mg once per week.
  • the estradiol serum levels are between about 35- 80 pg/ml, preferably between about 45-75 pg/ml, more preferably between about 50- 75 pg/ml.
  • the endometriosis patient with distinctive symptomatic pain is suffering from a chronic disease.
  • Surgical methods in sense of curative therapy as well as medicinal treatment to suppress the sexual steroid secretion of the patient often result only in a temporary improvement.
  • the relapse rate of the discomforts is very high and about 70% within 5 years after finishing therapy (Schweppe, 1999).
  • the radical surgical therapy in sense of hysterectomy with bilateral adnexectomy is no adequate therapy for the younger, premenopausal woman.
  • the chronical lack of estrogen leads to the following vegetative symptoms: hot flashes, sweating, dryness of the vagina, depressive feelings and also holds the risk of osteoporosis.
  • the alternative therapy with the synthetic steroidal compound Danazol may cause virilizing symptoms because of the androgenic effect.
  • Aim of the medicinal therapy of patients with endometriosis with symptomatic pain is to obtain a treatment without side effects, especially avoiding the negative effects of estrogen suppression and which is long-lasting after finishing therapy.
  • the specific pharmacological mode of action of LHRH antagonists allows new possibilities for treatment of endometriosis.
  • the weekly administration of an adequate dose of an LHRH antagonist, e.g. 3 mg Cetrotide ® s.c./ per week over a period of eight weeks leads to a controlled suppression of estrogen secretion so that serum concentrations between about 35 pg/ml and about 80 pg/ml, preferably between about 45-75 pg/ml, more preferably between about 50-75 pg/ml are obtained. In this serum concentration range no vegetative symptoms arise. Also the development of osteoporosis can be avoided. The symptomatic pain will be effectively suppressed in all stages of the disease (rAFS I - IV). In the stages rAFS I - II a clinical regression of the disease in sense of decrease of the implantation area is noticed (Felberbaum et. al., 2000).
  • the patient could take a contraceptive, preferably an oral contraceptive, preferably with gestagen components, unless there is a wish for pregnancy.
  • a contraceptive preferably an oral contraceptive, preferably with gestagen components
  • combinations with Lynestronol 2 mg with 0,04 mg Ethinylestradiol or 2,5 mg Lynestrenol with 0,05 mg of Ethinylestradiol e.g. Yermonil ® , Lyn-ratiopharm-Sequenz ® ) have to be mentioned.
  • a combination therapy with androgens other than 17-alpha-alkyl substituted testosterones such as danazol may also be applied subsequently to the short-term induction regimen with the LHRH antagonist either alone or in combination with non- steroidal anti-rheumatics and/or analgetics.
  • An example for a suitable androgene is halotestinTM (fluoximesterone).
  • a contraceptive preferably an oral contraceptive, preferably containing gestagens
  • a concomitant medication with appropriate non-steroidal anti-rheumatic drugs, e.g. diclophenac, ibuprofen, indometeacin, oxicam derivates or acetylsalicylic acid may be given.
  • an analgetic such as flupirtinmaleat (Katadolon ® ) can be administered.
  • gestagenic contraceptives preferably oral contraceptives
  • a daily, weekly or monthly therapy with the adequate dose of an LHRH antagonist as described above may be repeated.
  • Detailed information on the respective treatment options are given below. If the patient is absolutely free of pain treatment can be changed to gestagenic contraceptive, preferably oral contraceptive ⁇ in combination with concomitant medication of appropriate non-steroid anti-rheumatic drugs or analgetics.
  • compositions of the LHRH antagonist suitable for the therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction may be for example
  • acetate salt formulations in the concentration of 1.5 mg/1 ml to 5.0 mg /1 ml, preferably 2.5 mg/1 ml where the powder may be dissolved in Water for Injection (Wfl) or in Gluconic Acid (GA);
  • pamoate salt formulations in the concentration of 10 mg/1 ml to 30 mg/1 ml, preferably 15 mg/1 ml where the lyophylisate powder may be dissolved in Gluconic Acid (GA) or in Water for Injection (Wfl.
  • GA Gluconic Acid
  • Wfl Water for Injection
  • the improvement consisting of administration of an LHRH antagonist in the form of a short-term induction treatment for a period of about 4 to 12 weeks to a patient in need of such treatment, whereby subsequently the administration of the LHRH antagonist is ceased, is provided.
  • the duration of the short term induction treatment is about 4 to about 12 weeks, that means that the treatment can be between about 28 to about 84 days or from about one to about three months.
  • the improvement is provided, wherein the LHRH antagonist is administered such that the estrogen serum concentration level is between about 35 pg/ml and about 80 pg/ml, preferably between about 45-75 pg/ml, more preferably about 50-75 pg/ml.
  • the improvement in a method as mentioned above the improvement is provided, characterized in that the short-term induction treatment with the LHRH antagonist is followed by administration of a contraceptive, preferably an oral contraceptive.
  • the improvement in a method as mentioned above the improvement is provided, characterized in that the short-term induction treatment with the LHRH antagonist is followed by administration of a non-steroidal anti-rheumatic agent.
  • the improvement in a method as mentioned above the improvement is provided, characterized in that the short-term induction treatment with the LHRH antagonist is followed by administration of an analgetic.
  • the improvement in a method as mentioned above the improvement is provided, characterized in that the short-term induction treatment with the LHRH antagonist is followed by administration of an androgen other than a 17-alpha-alkyl substituted testosterone.
  • the improvement in a method as mentioned above the improvement is provided, characterized in that the short-term induction treatment with the LHRH antagonist is followed by the combined or separate administration of one or more active agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone or any combinations thereof.
  • a contraceptive preferably an oral contraceptive, a non-steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone or any combinations thereof.
  • the improvement is provided, characterized in that the LHRH antagonist is administered starting in the early to mid follicular phase, preferably on cycle day one to three.
  • the improvement is provided, characterized in that the LHRH antagonist is selected from the group consisting of cetrorelix, teverelix, ganirelix, antide, abarelix and D-63153.
  • the improvement in a method as mentioned above the improvement is provided, characterized in that the LHRH antagonist is administered during the short-term induction treatment for 4 to 12 weeks at a weekly dose of 3 to 10 mg per week.
  • the improvement in a method as mentioned above the improvement is provided, characterized in that the LHRH antagonist is administered during the short-term induction treatment for 4 to 12 weeks at a daily dose of 0.25 mg to 0.5 mg/day.
  • the improvement in a method as mentioned above the improvement is provided, characterized in that the LHRH antagonist is administered during the short-term induction treatment for 4 to 12 weeks at a monthly dose of 12 to 40 mg per month.
  • the improvement in a method as mentioned above the improvement is provided, characterized in that the LHRH antagonist is given for the induction treatment during 4 to 12 weeks and the treatment is repeated two or three times a year.
  • a pharmaceutical composition for treating extrauterine proliferation of endometrial tissue, chronic pelvic pain and/or fallopian tube obstruction comprising an LHRH antagonist and optionally one or more agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-steroidal anti-rheumatic agent, an analgetic agent, an androgen agent other than a 17-alpha-alkyl substituted testosterone or any combinations thereof, optionally together with pharmaceutically acceptable excipients, whereby the LH-RH antagonist is administered to a patient in need thereof in a short term induction treatment for a period of about 4 to 12 weeks, then the administration of the LH-RH antagonist is ceased and optionally the one or more agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone
  • excipients and dosage forms are for example described by K.H. Bauer, K - H. Fr ⁇ mming and C. F ⁇ hrer, Lehrbuch der Pharmazeutica Technologie, 6 th edition, Stuttgart 1999, pages 163-186 (excipients) and pages 227-386 (dosage forms), including the references as cited therein.
  • the LH-RH antagonist can be administered for example sucutaneous (s.c), intramuscular (i.m.) or inhalative.
  • agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone or any combinations thereof can be administered as known in the art (see for example the German, European or U.S. pharmacopoeia), preferably oral or inhalative.
  • a pharmaceutical composition as mentioned above wherein the LHRH antagonist is administered such that the estrogen serum concentration level is between about 35 pg/ml and about 80 pg/ml, preferably between about 45-75 pg/ml, more preferably about 50-75 pg/ml.
  • a pharmaceutical composition as mentioned above wherein the short-term induction treatment with the LHRH antagonist is followed by administration of a contraceptive, preferably an oral contraceptive.
  • a pharmaceutical composition as mentioned above wherein the short-term induction treatment with the LHRH antagonist is followed by administration of a non-steroidal anti-rheumatic agent.
  • a pharmaceutical composition as mentioned above wherein the short-term induction treatment with the LHRH antagonist is followed by administration of an analgetic.
  • a pharmaceutical composition as mentioned above wherein the short-term induction treatment with the LHRH antagonist is followed by administration of an androgen other than a 17- alpha-alkyl substituted testosterone.
  • a pharmaceutical composition as mentioned above wherein the short-term induction treatment with the LHRH antagonist is followed by the combined or separate administration of one or more active agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone or any combinations thereof.
  • a contraceptive preferably an oral contraceptive, a non-steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone or any combinations thereof.
  • a pharmaceutical composition as mentioned above wherein the LHRH antagonist is administered starting in the early to mid follicular phase, preferably on cycle day one to three.
  • a pharmaceutical composition as mentioned above wherein the LHRH antagonist is selected from the group consisting of cetrorelix, teverelix, ganirelix, antide, abarelix and D-63153.
  • a pharmaceutical composition as mentioned above wherein the LHRH antagonist is administered during the short-term induction treatment for 4 to 12 weeks at a weekly dose of 3 to 10 mg per week.
  • a pharmaceutical composition as mentioned above wherein the LHRH antagonist is administered during the short-term induction treatment for 4 to 12 weeks at a daily dose of 0.25 mg to 0.5 mg/day.
  • a pharmaceutical composition as mentioned above wherein the LHRH antagonist is administered during the short-term induction treatment for 4 to 12 weeks at a monthly dose of 12 to 40 mg per month.
  • a pharmaceutical composition as mentioned above wherein the LHRH antagonist is given for the induction treatment during 4 to 12 weeks and the treatment is repeated two or three times a year.
  • a pharmaceutical composition as mentioned above wherein the one or more active agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non- steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone or any combinations thereof, are in the same or separate dosage forms.
  • a contraceptive preferably an oral contraceptive, a non- steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone or any combinations thereof
  • an LH-RH antagonist for the preparation of a medicament for the therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and/or fallopian tube obstruction (FTO), whereby the LHRH antagonist is administered in the form of a short-term induction treatment for a period of about 4 to 12 weeks to a patient in need of such treatment and then the administration of the LHRH antagonist is ceased, is provided.
  • FTO fallopian tube obstruction
  • an LH-RH antagonist as mentioned above is provided wherein the LHRH antagonist is administered such that the estrogen serum concentration level is between about 35 pg/ml and about 80 pg/ml, preferably between about 45-75 pg/ml, more preferably about 50-75 pg/ml.
  • an LH-RH antagonist as mentioned above is provided, wherein the short-term induction treatment with the LHRH antagonist is followed by administration of a contraceptive, preferably an oral contraceptive.
  • an LH-RH antagonist as mentioned above is provided, wherein the short-term induction treatment with the LHRH antagonist is followed by administration of a non-steroidal anti-rheumatic agent.
  • an LH-RH antagonist as mentioned above is provided, wherein the short-term induction treatment with the LHRH antagonist is followed by administration of an analgetic.
  • an LH-RH antagonist as mentioned above is provided, wherein the short-term induction treatment with the LHRH antagonist is followed by administration of an androgen other than a 17- alpha-alkyl substituted testosterone.
  • a use of an LH-RH antagonist as mentioned above is provided, wherein the short-term induction treatment with the LHRH antagonist is followed by the combined or separate administration of one or more active agents selected from the group consisting of a contraceptive, preferably an oral contraceptive,, a non-steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone or any combinations thereof.
  • a use of an LH-RH antagonist as mentioned above is provided, wherein the LHRH antagonist is administered starting in the early to mid follicular phase, preferably on cycle day one to three.
  • an LH-RH antagonist as mentioned above is provided, wherein the LHRH antagonist is selected from the group consisting of cetrorelix, teverelix, ganirelix, antide, abarelix and D-63153.
  • an LH-RH antagonist as mentioned above is provided, wherein the LHRH antagonist is administered during the short-term induction treatment for 4 to 12 weeks at a weekly dose of 3 to 10 mg per week.
  • an LH-RH antagonist as mentioned above is provided, wherein the LHRH antagonist is administered during the short-term induction treatment for 4 to 12 weeks at a daily dose of 0.25 mg to 0.5 mg/day.
  • an LH-RH antagonist as mentioned above is provided, wherein the LHRH antagonist is administered during the short-term induction treatment for 4 to 12 weeks at a monthly dose of 12 to 40 mg per month.
  • an LH-RH antagonist as mentioned above is provided, wherein the LHRH antagonist is given for the induction treatment during 4 to 12 weeks and the treatment is repeated two or three times a year.
  • an LH-RH antagonist and one or more active agents as mentioned above is provided, wherein the LHRH antagonist is administered such that the estrogen serum concentration level is between about 35 pg/ml and about 80 pg/ml, preferably between about 45-75 pg/ml, more preferably about 50-75 pg/ml.
  • an LH-RH antagonist and one or more active agents as mentioned above is provided, wherein the short- term induction treatment with the LHRH antagonist is followed by administration of a contraceptive, preferably an oral contraceptive.
  • an LH-RH antagonist and one or more active agents as mentioned above is provided, wherein the short- term induction treatment with the LHRH antagonist is followed by administration of a non-steroidal anti-rheumatic agent.
  • an LH-RH antagonist and one or more active agents as mentioned above is provided, wherein the short- term induction treatment with the LHRH antagonist is followed by administration of an analgetic.
  • an LH-RH antagonist and one or more active agents as mentioned above is provided, wherein the short- term induction treatment with the LHRH antagonist is followed by administration of an androgen other than a 17-alpha-alkyl substituted testosterone.
  • an LH-RH antagonist and one or more active agents as mentioned above is provided, wherein the short- term induction treatment with the LHRH antagonist is followed by the combined or separate administration of one or more active agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-steroidal anti- rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone or any combinations thereof.
  • a contraceptive preferably an oral contraceptive, a non-steroidal anti- rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone or any combinations thereof.
  • an LH-RH antagonist and one or more active agents as mentioned above is provided, wherein the LHRH antagonist is administered starting in the early to mid follicular phase, preferably on cycle day one to three.
  • an LH-RH antagonist and one or more active agents as mentioned above is provided, wherein the LHRH antagonist is selected from the group consisting of cetrorelix, teverelix, ganirelix, antide, abarelix and D-63153.
  • an LH-RH antagonist and one or more active agents as mentioned above is provided, wherein the LHRH antagonist is administered during the short-term induction treatment for 4 to 12 weeks at a weekly dose of 3 to 10 mg per week.
  • an LH-RH antagonist and one or more active agents as mentioned above is provided, wherein the LHRH antagonist is administered during the short-term induction treatment for 4 to 12 weeks at a daily dose of 0.25 mg to 0.5 mg/day.
  • an LH-RH antagonist and one or more active agents as mentioned above is provided, wherein the LHRH antagonist is administered during the short-term induction treatment for 4 to 12 weeks at a monthly dose of 12 to 40 mg per month.
  • an LH-RH antagonist and one or more active agents as mentioned above is provided, wherein the LHRH antagonist is given for the induction treatment during 4 to 12 weeks and the treatment is repeated two or three times a year.

Abstract

The present invention provides a method for therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction by short term induction treatment with an LH-RH antagonist for 4 to 12 weeks. According to another aspect of the present invention, the short term LH-RH treatment is followed by the combined or separate administration of one or more active agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone or any combinations thereof. According to a further aspect of the present invention a pharmaceutical composition comprising an LHRH antagonist and one or more active agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone or any combinations thereof are provided.

Description

Method for the therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction
Field of Invention
Endometriosis is one of the most frequently encountered pathologies diagnosed amongst gynecological patients. For example, between 10% and 25% of women presenting with gynecological symptoms in UK and in the USA are affected. Clinical diagnosis is made usually by laparoscopic observation of hemorrhagic or fibrotic foci on the pelvic organs. The ectopic endometrial tissue responds to ovarian hormones undergoing cyclic changes. The cyclical bleeding from the endometric deposit contributes to a local inflammatory reaction. Endometriosis commonly affects women during their childbearing years with an incidence of at least 1 % (see Shaw, R.W. (1993), An Atlas of Endometriosis. The Parthenon Publishing Group).
Endometriosis is usually classified into endometriosis (genitalis) interna (adenomyosis), endometriosis genitalis externa and endometriosis extragenitalis.
Chronic pelvic pain may occur either in relation to endometriosis or as an independent disease.
Fallopian tube obstruction (FTO) is a relatively common disease and may account to for up to 20 % of cases of tubal infertility (see Winfield, A.C. et al., Apparent cornual occlusion in hysterosalpingography: Reversal by glucagon. AJR Am J Roentgenol 1982; 139: 525 - 527).
Background information and Prior Art
Sampson suggested that menstrual regurgitation and subsequent implantation of endometrial tissue on the peritoneal face results in endometriosis [Sampson, J.A. (1927), Peritoneal endometriosis due to menstrual dissemination of the endometrial tissue into the peritoneal cavitiy. Am. J. Obstet. Gynecol., 14, 422.]
Several aetiologic factors may be involved in the pathogenesis of endometriosis :
Dmowski et. al. suggested that genetic and immunological factors lead to endometriosis [Dmowski, W.P., Steele, R.W. and Baker, G.F. (1981 ). Deficient cellular immunity in endometriosis. Am. J. Obstet. Gynecol., 141 , 377] Vascular and lymphatic embolization to distant sites has been demonstrated and explains the (rare) finding of endometriosis outside the peritoneal cavity, e.g. skin, lung, kidney.
Cells lining the Mϋllerian duct arise from primitive cells which differentiate into peritoneal cells and the cells on the surface of the ovaries. It is proposed that these adult cells undergo de-differentiation back to their primitive origin and then transform into endometrial cells [ Levander, G. (1941 ), Bone formation by induction. An experimental study. Arch. Klin. Chir., 202, 497]
Dysmenorrhea, acute or chronic pelvic pain, dyspareunia, and infertility perform the most frequent clinical symptoms reported.
FTO represents a heterogenous group of underlying pathology, preliminary intrinsic occlusion or extrinsic compression from estrogen-sensitive disorders, such as endometriosis, adenomyosis, endosalpingiosis, and myomata. FTO is frequently diagnosed by hysterosalpingography, besides laparascopy.
First choice of treatment comprises laparoscopic removal of endometric lesions. This procedure may be followed by the treatment with Danazol or LHRH agonist (for a period of six months). Women being treated with Danazol might experience gastrointestinal and hepatic disorders as well as severe androgenic side effects.
It was also proposed from a theoretical viewpoint for treatment of endometriosis and uterine myoma to use the immediate suppression by administration of a LHRH antagonist to reducing the duration of treatment and faster improvement of subjective symtoms [Th. Reissmann et al. Human Reproduction vol. 10 No. 8 pp.1974-1981 ,(1995)] Further Hodgen teaches in the US Patent 5,658,884 a regime for therapeutic management of a gonadal dependent condition by reducing the estrogen supply by means of long-term administration of an GnRH antagonist for 6 months or longer in an amount effective to inhibit proliferation of endometrial tissue without substantially stopping the production of endogenous estrogen. For this purpose, Hodgen teaches such a regimen or dose of GnRH antagonist to achieve a 24 hour serum estradiol level in the range of about 25 to 50 and preferably about 35 to 45 pg/ml. However, Hodgen does not describe estradiol serum levels oscillating between 50 pg/ml and 75 pg/ml. Moreover, Hodgen only teaches in the US Patent 5,658,884 a continuous long-term treatment (on a daily or periodic basis, the latter meaning a weekly or monthly administration) but not a short-term induction treatment for only 4 to 12 weeks. Hodgen also does not describe any combination therapy comprising the GnRH antagonist in the treatment of endometrosis. The treatment is only described on monkeys and also includes the performance of a costly and repeated progesterone challenge test to provide an 24 hour average serum estradiol level of 30 to 50 pg/ml.
As a consequence of the flare-up effect of LHRH-agonistic therapy an exacerbation of symptoms might occur during some days. Following prolonged treatment which is required to avoid the re-proliferation of endometric tissue hormonal withdrawal symptoms as well as demineralization of bones occur.
Therefore, effective drug therapy should immediately reduce the residual extrauterine endometrial tissue present after laparoscopic surgery. Duration of therapy should be only 4 to 12 weeks without the occurrence of any major hormonal withdrawal symptoms or ovarian cyst formation.
LHRH antagonists exert an immediate onset of hormonal suppression, and therefore benign gynecological tumors, such as uterine fibroids decrease within short time [Human Reproduction 1998, 13 ]
Object of the Invention The present invention relates to the improvement of the medical treatment of extrauterine proliferation of endometrial tissue, i. e. the administration of LHRH antagonists in patients with clinical symptoms of endometriosis, the improvement consisting of : immediate reduction of ectopic endometrial tissue immediate cessation of symptoms, e.g. severe pain, chronic pelvic pain and dysmenorrhea prevention of any progress of the disease avoidance of hormonal withdrawal symptoms prevention of ovarian cyst formation, demineralization of bones as well as of gastrointestinal or hepatic disorders.
The inventive medical therapy can start in the early to mid follicular phase, preferably on cycle day one to three. During the treatment the estradiol serum concentration levels are kept between 35 pg/ml and 80 pg/ml, preferably between about 45-75 pg/ml, more preferably between about 50-75 pg/ml. The LHRH antagonist is administered only for 4 to 12 weeks (short-term induction treatment), either by daily, weekly or monthly administration. Following the short-term induction treatment, the administration of a contraceptive, a non-steroidal anti-rheumatic, an analgetic, an androgen other than 17-alpha-alkyl substituted testosterone or any combinations thereof is provided according to the present invention.
Summary of the Invention
In the treatment of extrauterine endometrial tissue with an LHRH antagonist, therapy is started on menstrual cycle day one to three. Before starting LHRH- antagonist therapy the diagnosis is performed by laparoscopy. In cases of severe pain, LHRH antagonist therapy might be initiated without prior laparascopy.
Therapy will continue until clinical symptomatology has resolved and no proliferation of the endometrium is seen. Due to the immediate onset of suppression of the gonadotropins LH and FSH as well of sex steroids estradiol and progesterone no further proliferation of the endometrium occurs. Benign tumors or other sex steroid dependent lesions, like endometriosis decrease within four to twelve weeks of therapy. Due to the lack of flare-up no ovarian cysts develop.
Furthermore, no hormonal withdrawal symptoms are seen as the estradiol values are kept in the range of the early follicular phase of 35 to 80 pg/ml, preferably between about 45-75 pg/ml, more preferably between about 50-75 pg/ml without further increase or decrease. No titering of the dosage of the LHRH antagonist , e.g. by conducting a costly progesterone challenge test, is necessary.
The method of therapeutic management of extrauterine proliferation of endometrial tissue the improvement according to the invention therefore embraces: immediate reduction of ectopic endometrial tissue prevention of any progress of the disease avoidance of hormonal withdrawal symptoms prevention of ovarian cyst formation, demineralization of bones as well as of gastrointestinal or hepatic disorders start of medical therapy on cycle day one to three and maintenance of estradiol levels at values of the early follicular phase throughout the entire duration of treatment by means of administration of a LHRH antagonist wherein the antagonist is preferabely cetrorelix, teverelix, ganirelix, antide or abarelix. The antagonist can also be the LHRH antagonist D-63153 (Ac-D-Nal-D-pCI-Phe-D-Pal-Ser-N-Me-Tyr-D- Hci-Nle-Arg-Pro-D-Ala-NH2) as described in the German Patent Application No. 199 11 771.3 filed on March 11 , 1999.
The LHRH antagonist may be given for 4 to 12 weeks in a weekly dose of 3 to 10 mg per week or for 4 to 12 weeks in a daily dose of 0.25 mg to 0.5 mg/day.
It is also possible to give the LHRH antagonist 4 to 12 weeks in a monthly dose of 12 to 40 mg per month.
In a repeat therapeutic treatment the LHRH antagonist is given for 4 to 12 weeks and the treatment is repeated two or three times a year, whereby a repeated treatment does not following directly after a short-term induction treatment. Usually a period of time of weeks or months, where no LHRH antagonist is administered, is between the end of the short-term induction treatment and the start of the repeat treatment.
To demonstrate the feasibility to maintain a low estradiol secretion under adjusted LHRH- antagonist treatment so that a therapeutic suppression occurs without withdrawal symtoms nine patients with confirmed endometriosis were treated with 3 mg of Cetrorelix acetate s.c. by weekly administration for 8 weeks. While patients compliance was excellent avoiding any hot flushes or other withdrawal symptoms and without any progress of the disease confimed by 2 nd look laparascopy the mean estradiol serum concentrations oscillated between 37 pg/ml and 64 pg/ml, preferably between 45-75 pg/ml, more preferably between about 50-75 pg/ml. Histological biopsies showed no proliferation of the endometrium at the end of treatment. No ovarian cyst formation occurred.
The figure 1 shows the continuous estradiol suppression to values of the early follicular phase (range of 35 pg/ml to 80 pg/ml, preferably between 45-75 pg/ml, more preferably between about 50-75 pg/ml) obtained in patients with endometriosis by a weekly dose of 3 mg of Cetrorelix (LHRH antagonist) for 8 weeks. Immediate and continuous suppression of estradiol levels is obtained without any signs of estradiol withdrawal symptoms and without proliferation of the endometrium at the end of treatment.
Fig. 2 shows estradiol serum levels after administration of cetrorelix at a weekly dose of 1 mg resp. 3 mg once per week. The estradiol serum levels are between about 35- 80 pg/ml, preferably between about 45-75 pg/ml, more preferably between about 50- 75 pg/ml.
The endometriosis patient with distinctive symptomatic pain is suffering from a chronic disease. Surgical methods in sense of curative therapy as well as medicinal treatment to suppress the sexual steroid secretion of the patient often result only in a temporary improvement. The relapse rate of the discomforts is very high and about 70% within 5 years after finishing therapy (Schweppe, 1999).
At the same time the radical surgical therapy and the suppression of the estrogen secretion leads to considerable side effects. The radical surgical therapy in sense of hysterectomy with bilateral adnexectomy is no adequate therapy for the younger, premenopausal woman. The chronical lack of estrogen leads to the following vegetative symptoms: hot flashes, sweating, dryness of the vagina, depressive feelings and also holds the risk of osteoporosis. The alternative therapy with the synthetic steroidal compound Danazol may cause virilizing symptoms because of the androgenic effect.
Aim of the medicinal therapy of patients with endometriosis with symptomatic pain is to obtain a treatment without side effects, especially avoiding the negative effects of estrogen suppression and which is long-lasting after finishing therapy. The specific pharmacological mode of action of LHRH antagonists allows new possibilities for treatment of endometriosis.
The weekly administration of an adequate dose of an LHRH antagonist, e.g. 3 mg Cetrotide® s.c./ per week over a period of eight weeks leads to a controlled suppression of estrogen secretion so that serum concentrations between about 35 pg/ml and about 80 pg/ml, preferably between about 45-75 pg/ml, more preferably between about 50-75 pg/ml are obtained. In this serum concentration range no vegetative symptoms arise. Also the development of osteoporosis can be avoided. The symptomatic pain will be effectively suppressed in all stages of the disease (rAFS I - IV). In the stages rAFS I - II a clinical regression of the disease in sense of decrease of the implantation area is noticed (Felberbaum et. al., 2000).
In a preferred embodiment of this invention, after this treatment period of eight to twelve weeks the patient could take a contraceptive, preferably an oral contraceptive, preferably with gestagen components, unless there is a wish for pregnancy. In this connection combinations with Lynestronol 2 mg with 0,04 mg Ethinylestradiol or 2,5 mg Lynestrenol with 0,05 mg of Ethinylestradiol (e.g. Yermonil®, Lyn-ratiopharm-Sequenz®) have to be mentioned.
A combination therapy with androgens other than 17-alpha-alkyl substituted testosterones such as danazol may also be applied subsequently to the short-term induction regimen with the LHRH antagonist either alone or in combination with non- steroidal anti-rheumatics and/or analgetics. An example for a suitable androgene is halotestin™ (fluoximesterone).
The treatment with a contraceptive, preferably an oral contraceptive, preferably containing gestagens, should be individually continued until typical pain sensation occurs. In this stage the patient will have relatively small menstrual bleeding as an effect of the gestagen component of this contraceptive, preferably oral contraceptive. For covering also the especially critical pre-menstrual and menstrual days with regard to pain sensation in this phase a concomitant medication with appropriate non-steroidal anti-rheumatic drugs, e.g. diclophenac, ibuprofen, indometeacin, oxicam derivates or acetylsalicylic acid may be given. Also an analgetic such as flupirtinmaleat (Katadolon®) can be administered.
If further pain symptoms occur during this combination therapy with gestagenic contraceptives, preferably oral contraceptives, a daily, weekly or monthly therapy with the adequate dose of an LHRH antagonist as described above may be repeated. Detailed information on the respective treatment options are given below. If the patient is absolutely free of pain treatment can be changed to gestagenic contraceptive, preferably oral contraceptive^ in combination with concomitant medication of appropriate non-steroid anti-rheumatic drugs or analgetics.
This therapy using the intermittent administration of an LHRH antagonist leads to a new and innovative unlimited treatment without side effects and lowers treatment burden for the patient significantly. Pharmaceutical Formulations Suitable for Treatment
Pharmaceutical formulations of the LHRH antagonist suitable for the therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction may be for example
a) acetate salt formulations in the concentration of 1 mg/1 ml or lower where the powder may be dissolved in Water for Injection (Wfl) or in Gluconic Acid (GA);
b) acetate salt formulations in the concentration of 1.5 mg/1 ml to 5.0 mg /1 ml, preferably 2.5 mg/1 ml where the powder may be dissolved in Water for Injection (Wfl) or in Gluconic Acid (GA);
c) pamoate salt formulations in the concentration of 10 mg/1 ml to 30 mg/1 ml, preferably 15 mg/1 ml where the lyophylisate powder may be dissolved in Gluconic Acid (GA) or in Water for Injection (Wfl.
According to one aspect of the present invention in the method of therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and/or fallopian tube obstruction (FTO), the improvement consisting of administration of an LHRH antagonist in the form of a short-term induction treatment for a period of about 4 to 12 weeks to a patient in need of such treatment, whereby subsequently the administration of the LHRH antagonist is ceased, is provided.
The duration of the short term induction treatment is about 4 to about 12 weeks, that means that the treatment can be between about 28 to about 84 days or from about one to about three months.
According to another aspect of the present invention in a method as mentioned above the improvement is provided, wherein the LHRH antagonist is administered such that the estrogen serum concentration level is between about 35 pg/ml and about 80 pg/ml, preferably between about 45-75 pg/ml, more preferably about 50-75 pg/ml.
According to another aspect of the present invention in a method as mentioned above the improvement is provided, characterized in that the short-term induction treatment with the LHRH antagonist is followed by administration of a contraceptive, preferably an oral contraceptive.
According to another aspect of the present invention in a method as mentioned above the improvement is provided, characterized in that the short-term induction treatment with the LHRH antagonist is followed by administration of a non-steroidal anti-rheumatic agent.
According to another aspect of the present invention in a method as mentioned above the improvement is provided, characterized in that the short-term induction treatment with the LHRH antagonist is followed by administration of an analgetic.
According to another aspect of the present invention in a method as mentioned above the improvement is provided, characterized in that the short-term induction treatment with the LHRH antagonist is followed by administration of an androgen other than a 17-alpha-alkyl substituted testosterone.
According to another aspect of the present invention in a method as mentioned above the improvement is provided, characterized in that the short-term induction treatment with the LHRH antagonist is followed by the combined or separate administration of one or more active agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone or any combinations thereof.
According to another aspect of the present invention in a method as mentioned above the improvement is provided, characterized in that the LHRH antagonist is administered starting in the early to mid follicular phase, preferably on cycle day one to three.
According to another aspect of the present invention in a method as mentioned above the improvement is provided, characterized in that the LHRH antagonist is selected from the group consisting of cetrorelix, teverelix, ganirelix, antide, abarelix and D-63153.
According to another aspect of the present invention in a method as mentioned above the improvement is provided, characterized in that the LHRH antagonist is administered during the short-term induction treatment for 4 to 12 weeks at a weekly dose of 3 to 10 mg per week.
According to another aspect of the present invention in a method as mentioned above the improvement is provided, characterized in that the LHRH antagonist is administered during the short-term induction treatment for 4 to 12 weeks at a daily dose of 0.25 mg to 0.5 mg/day.
According to another aspect of the present invention in a method as mentioned above the improvement is provided, characterized in that the LHRH antagonist is administered during the short-term induction treatment for 4 to 12 weeks at a monthly dose of 12 to 40 mg per month.
According to another aspect of the present invention in a method as mentioned above the improvement is provided, characterized in that the LHRH antagonist is given for the induction treatment during 4 to 12 weeks and the treatment is repeated two or three times a year.
According to a further aspect of the present invention a pharmaceutical composition for treating extrauterine proliferation of endometrial tissue, chronic pelvic pain and/or fallopian tube obstruction (FTO) comprising an LHRH antagonist and optionally one or more agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-steroidal anti-rheumatic agent, an analgetic agent, an androgen agent other than a 17-alpha-alkyl substituted testosterone or any combinations thereof, optionally together with pharmaceutically acceptable excipients, whereby the LH-RH antagonist is administered to a patient in need thereof in a short term induction treatment for a period of about 4 to 12 weeks, then the administration of the LH-RH antagonist is ceased and optionally the one or more agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone or any combinations thereof, are administered together or separately to the patient is provided.
Suitable excipients and dosage forms are for example described by K.H. Bauer, K - H. Frόmming and C. Fϋhrer, Lehrbuch der Pharmazeutischen Technologie, 6th edition, Stuttgart 1999, pages 163-186 (excipients) and pages 227-386 (dosage forms), including the references as cited therein.
The LH-RH antagonist can be administered for example sucutaneous (s.c), intramuscular (i.m.) or inhalative. The agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone or any combinations thereof can be administered as known in the art (see for example the German, European or U.S. pharmacopoeia), preferably oral or inhalative.
According to another aspect of the present invention, a pharmaceutical composition as mentioned above is provided wherein the LHRH antagonist is administered such that the estrogen serum concentration level is between about 35 pg/ml and about 80 pg/ml, preferably between about 45-75 pg/ml, more preferably about 50-75 pg/ml.
According to another aspect of the present invention, a pharmaceutical composition as mentioned above is provided wherein the short-term induction treatment with the LHRH antagonist is followed by administration of a contraceptive, preferably an oral contraceptive. According to another aspect of the present invention, a pharmaceutical composition as mentioned above is provided wherein the short-term induction treatment with the LHRH antagonist is followed by administration of a non-steroidal anti-rheumatic agent.
According to another aspect of the present invention, a pharmaceutical composition as mentioned above is provided wherein the short-term induction treatment with the LHRH antagonist is followed by administration of an analgetic.
According to another aspect of the present invention, a pharmaceutical composition as mentioned above is provided wherein the short-term induction treatment with the LHRH antagonist is followed by administration of an androgen other than a 17- alpha-alkyl substituted testosterone.
According to another aspect of the present invention, a pharmaceutical composition as mentioned above is provided wherein the short-term induction treatment with the LHRH antagonist is followed by the combined or separate administration of one or more active agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone or any combinations thereof.
According to another aspect of the present invention, a pharmaceutical composition as mentioned above is provided wherein the LHRH antagonist is administered starting in the early to mid follicular phase, preferably on cycle day one to three.
According to another aspect of the present invention, a pharmaceutical composition as mentioned above is provided wherein the LHRH antagonist is selected from the group consisting of cetrorelix, teverelix, ganirelix, antide, abarelix and D-63153.
According to another aspect of the present invention, a pharmaceutical composition as mentioned above is provided wherein the LHRH antagonist is administered during the short-term induction treatment for 4 to 12 weeks at a weekly dose of 3 to 10 mg per week.
According to another aspect of the present invention, a pharmaceutical composition as mentioned above is provided wherein the LHRH antagonist is administered during the short-term induction treatment for 4 to 12 weeks at a daily dose of 0.25 mg to 0.5 mg/day.
According to another aspect of the present invention, a pharmaceutical composition as mentioned above is provided wherein the LHRH antagonist is administered during the short-term induction treatment for 4 to 12 weeks at a monthly dose of 12 to 40 mg per month.
According to another aspect of the present invention, a pharmaceutical composition as mentioned above is provided wherein the LHRH antagonist is given for the induction treatment during 4 to 12 weeks and the treatment is repeated two or three times a year.
According to another aspect of the present invention, a pharmaceutical composition as mentioned above is provided, wherein the the one or more active agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non- steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone or any combinations thereof, are in the same or separate dosage forms.
According to another aspect of the present invention, a use of an LH-RH antagonist for the preparation of a medicament for the therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and/or fallopian tube obstruction (FTO), whereby the LHRH antagonist is administered in the form of a short-term induction treatment for a period of about 4 to 12 weeks to a patient in need of such treatment and then the administration of the LHRH antagonist is ceased, is provided. According to another aspect of the present invention, a use of an LH-RH antagonist as mentioned above is provided wherein the LHRH antagonist is administered such that the estrogen serum concentration level is between about 35 pg/ml and about 80 pg/ml, preferably between about 45-75 pg/ml, more preferably about 50-75 pg/ml.
According to another aspect of the present invention, a use of an LH-RH antagonist as mentioned above is provided, wherein the short-term induction treatment with the LHRH antagonist is followed by administration of a contraceptive, preferably an oral contraceptive.
According to another aspect of the present invention, a use of an LH-RH antagonist as mentioned above is provided, wherein the short-term induction treatment with the LHRH antagonist is followed by administration of a non-steroidal anti-rheumatic agent.
According to another aspect of the present invention, a use of an LH-RH antagonist as mentioned above is provided, wherein the short-term induction treatment with the LHRH antagonist is followed by administration of an analgetic.
According to another aspect of the present invention, a use of an LH-RH antagonist as mentioned above is provided, wherein the short-term induction treatment with the LHRH antagonist is followed by administration of an androgen other than a 17- alpha-alkyl substituted testosterone.
According to another aspect of the present invention, a use of an LH-RH antagonist as mentioned above is provided, wherein the short-term induction treatment with the LHRH antagonist is followed by the combined or separate administration of one or more active agents selected from the group consisting of a contraceptive, preferably an oral contraceptive,, a non-steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone or any combinations thereof. According to another aspect of the present invention, a use of an LH-RH antagonist as mentioned above is provided, wherein the LHRH antagonist is administered starting in the early to mid follicular phase, preferably on cycle day one to three.
According to another aspect of the present invention, a use of an LH-RH antagonist as mentioned above is provided, wherein the LHRH antagonist is selected from the group consisting of cetrorelix, teverelix, ganirelix, antide, abarelix and D-63153.
According to another aspect of the present invention, a use of an LH-RH antagonist as mentioned above is provided, wherein the LHRH antagonist is administered during the short-term induction treatment for 4 to 12 weeks at a weekly dose of 3 to 10 mg per week.
According to another aspect of the present invention, a use of an LH-RH antagonist as mentioned above is provided, wherein the LHRH antagonist is administered during the short-term induction treatment for 4 to 12 weeks at a daily dose of 0.25 mg to 0.5 mg/day.
According to another aspect of the present invention, a use of an LH-RH antagonist as mentioned above is provided, wherein the LHRH antagonist is administered during the short-term induction treatment for 4 to 12 weeks at a monthly dose of 12 to 40 mg per month.
According to another aspect of the present invention, a use of an LH-RH antagonist as mentioned above is provided, wherein the LHRH antagonist is given for the induction treatment during 4 to 12 weeks and the treatment is repeated two or three times a year.
According to another aspect of the present invention, a use of an LH-RH antagonist and one or more active agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone, or any combinations thereof, for the preparation of a medicament for the therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and/or fallopian tube obstruction (FTO), whereby the LHRH antagonist is administered in the form of a short-term induction treatment for a period of about 4 to 12 weeks to a patient in need of such treatment, then the administration of the LHRH antagonist is ceased and the one or more active agent selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-steroidal anti- rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone, or any combinations thereof, are administered together or separately to the patient, is provided.
According to another aspect of the present invention the use of an LH-RH antagonist and one or more active agents as mentioned above is provided, wherein the LHRH antagonist is administered such that the estrogen serum concentration level is between about 35 pg/ml and about 80 pg/ml, preferably between about 45-75 pg/ml, more preferably about 50-75 pg/ml.
According to another aspect of the present invention the use of an LH-RH antagonist and one or more active agents as mentioned above is provided, wherein the short- term induction treatment with the LHRH antagonist is followed by administration of a contraceptive, preferably an oral contraceptive.
According to another aspect of the present invention the use of an LH-RH antagonist and one or more active agents as mentioned above is provided, wherein the short- term induction treatment with the LHRH antagonist is followed by administration of a non-steroidal anti-rheumatic agent.
According to another aspect of the present invention the use of an LH-RH antagonist and one or more active agents as mentioned above is provided, wherein the short- term induction treatment with the LHRH antagonist is followed by administration of an analgetic.
According to another aspect of the present invention the use of an LH-RH antagonist and one or more active agents as mentioned above is provided, wherein the short- term induction treatment with the LHRH antagonist is followed by administration of an androgen other than a 17-alpha-alkyl substituted testosterone.
According to another aspect of the present invention the use of an LH-RH antagonist and one or more active agents as mentioned above is provided, wherein the short- term induction treatment with the LHRH antagonist is followed by the combined or separate administration of one or more active agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-steroidal anti- rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone or any combinations thereof.
According to another aspect of the present invention the use of an LH-RH antagonist and one or more active agents as mentioned above is provided, wherein the LHRH antagonist is administered starting in the early to mid follicular phase, preferably on cycle day one to three.
According to another aspect of the present invention the use of an LH-RH antagonist and one or more active agents as mentioned above is provided, wherein the LHRH antagonist is selected from the group consisting of cetrorelix, teverelix, ganirelix, antide, abarelix and D-63153.
According to another aspect of the present invention the use of an LH-RH antagonist and one or more active agents as mentioned above is provided, wherein the LHRH antagonist is administered during the short-term induction treatment for 4 to 12 weeks at a weekly dose of 3 to 10 mg per week.
According to another aspect of the present invention the use of an LH-RH antagonist and one or more active agents as mentioned above is provided, wherein the LHRH antagonist is administered during the short-term induction treatment for 4 to 12 weeks at a daily dose of 0.25 mg to 0.5 mg/day.
According to another aspect of the present invention the use of an LH-RH antagonist and one or more active agents as mentioned above is provided, wherein the LHRH antagonist is administered during the short-term induction treatment for 4 to 12 weeks at a monthly dose of 12 to 40 mg per month.
According to another aspect of the present invention the use of an LH-RH antagonist and one or more active agents as mentioned above is provided, wherein the LHRH antagonist is given for the induction treatment during 4 to 12 weeks and the treatment is repeated two or three times a year.

Claims

- - Claims :
1. In the method of therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and/or fallopian tube obstruction (FTO), the improvement consisting of administration of an LHRH antagonist in the form of a short-term induction treatment for a period of about 4 to 12 weeks to a patient in need of such treatment, whereby subsequently the administration of the LHRH antagonist is ceased.
2. A method according to claim 1 wherein the LHRH antagonist is administered such that the estrogen serum concentration level is between about 35 pg/ml and about 80 pg/ml, preferably between about 45-75 pg/ml, more preferably about 50-75 pg/ml.
3. A method according to claim 1 wherein the short-term induction treatment with the LHRH antagonist is followed by administration of a contraceptive, preferably an oral contraceptive.
4. A method according to claim 1 wherein the short-term induction treatment with the LHRH antagonist is followed by administration of a non-steroidal anti- rheumatic agent.
5. A method according to claim 1 wherein the short-term induction treatment with the LHRH antagonist is followed by administration of an analgetic.
6. A method according to claim 1 wherein the short-term induction treatment with the LHRH antagonist is followed by administration of an androgen other than a 17-alpha-alkyl substituted testosterone.
7. A method according to claim 1 wherein the short-term induction treatment with the LHRH antagonist is followed by the combined or separate administration of one or more active agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone or any combinations thereof.
8. A method according to claim 1 wherein the LHRH antagonist is administered starting in the early to mid follicular phase, preferably on cycle day one to three.
9. A method according to claim 1 wherein the LHRH antagonist is selected from the group consisting of cetrorelix, teverelix, ganirelix, antide, abarelix and D-63153.
10. A method according to claim 1 wherein the LHRH antagonist is administered during the short-term induction treatment for about 4 to 12 weeks at a weekly dose of about 3 to 10 mg per week.
11. A method according to claim 1 wherein the LHRH antagonist is administered during the short-term induction treatment for about 4 to 12 weeks at a daily dose of about 0.25 mg to 0.5 mg/day.
12. A method according to claim 1 wherein the LHRH antagonist is administered during the short-term induction treatment for about 4 to 12 weeks at a monthly dose of about 12 to 40 mg per month.
13. A method according to claim 1 wherein the LHRH antagonist is given for the induction treatment during about 4 to 12 weeks and the treatment is repeated two or three times a year.
14. A pharmaceutical composition for treating extrauterine proliferation of endometrial tissue, chronic pelvic pain and/or fallopian tube obstruction (FTO) comprising an LHRH antagonist and optionally one or more agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non- steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha- alkyl substituted testosterone or any combinations thereof, optionally together with pharmaceutically acceptable excipients, whereby the LH-RH antagonist is administered to a patient in need thereof in a short term induction treatment for a period of about 4 to 12 weeks, then the administration of the LH-RH antagonist is ceased and optionally the one or more agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-steroidal anti- rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone or any combinations thereof, are administered together or separately to the patient.
15. Pharmaceutical composition according to claim 14 wherein the LHRH antagonist is administered such that the estrogen serum concentration level is between about 35 pg/ml and about 80 pg/ml, preferably between about 45-75 pg/ml, more preferably about 50-75 pg/ml.
16. Pharmaceutical composition according to claims 14 or 15 wherein the short-term induction treatment with the LHRH antagonist is followed by administration of a contraceptive, preferably an oral contraceptive.
17. Pharmaceutical composition according to any one of the claims 14 to 16 wherein the short-term induction treatment with the LHRH antagonist is followed by administration of a non-steroidal anti-rheumatic agent.
18. Pharmaceutical composition according to any one of the claims 14 to 17 wherein the short-term induction treatment with the LHRH antagonist is followed by administration of an analgetic.
19. Pharmaceutical composition according to any one of the claims 14 to 18 wherein the short-term induction treatment with the LHRH antagonist is followed by administration of an androgen other than a 17-alpha-alkyl substituted testosterone.
20. Pharmaceutical composition according to any one of the claims 14 to 19 wherein the short-term induction treatment with the LHRH antagonist is followed by the combined or separate administration of one or more active agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non- steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha- alkyl substituted testosterone or any combinations thereof.
21. Pharmaceutical composition according to any one of the claims 14 to 20 wherein the LHRH antagonist is administered starting in the early to mid follicular phase, preferably on cycle day one to three.
22. A pharmaceutical composition according to any one of claims 14 to 21 wherein the LHRH antagonist is selected from the group consisting of cetrorelix, teverelix, ganirelix, antide, abarelix and D-63153.
23. Pharmaceutical composition according to any one of claims 14 to 22 wherein the LHRH antagonist is administered during the short-term induction treatment for about 4 to 12 weeks at a weekly dose of about 3 to about 10 mg per week.
24. A pharmaceutical composition according to any one of claims 14 to 23 wherein the LHRH antagonist is administered during the short-term induction treatment for about 4 to 12 weeks at a daily dose of about 0.25 mg to about 0.5 mg/day.
25. Pharmaceutical composition according to any one of claims 14 to 24 wherein the LHRH antagonist is administered during the short-term induction treatment for about 4 to 12 weeks at a monthly dose of about 12 to 40 mg per month.
26. Pharmaceutical composition according to any one of claims 14 to 25 wherein the LHRH antagonist is given for the induction treatment during about 4 to 12 weeks and the treatment is repeated two or three times a year.
27. Pharmaceutical composition according to any one of claims 14 to 26, wherein the the one or more active agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone or any combinations thereof, are in the same or separate dosage forms.
28. Use of an LH-RH antagonist for the preparation of a medicament for the therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and/or fallopian tube obstruction (FTO), whereby the LHRH antagonist is administered in the form of a short-term induction treatment for a period of about 4 to 12 weeks to a patient in need of such treatment and then the administration of the LHRH antagonist is ceased.
29. Use of an LH-RH antagonist according to claim 28 wherein the LHRH antagonist is administered such that the estrogen serum concentration level is between about 35 pg/ml and about 80 pg/ml, preferably between about 45-75 pg/ml, more preferably about 50-75 pg/ml.
30. Use of an LH-RH antagonist according to claim 28 or 29 wherein the short-term induction treatment with the LHRH antagonist is followed by administration of a contraceptive, preferably an oral contraceptive.
31 . Use of an LH-RH antagonist according to any one of claims 28 to 30 wherein the short-term induction treatment with the LHRH antagonist is followed by administration of a non-steroidal anti-rheumatic agent.
32. Use of an LH-RH antagonist according to any one of claims 28 to 31 wherein the short-term induction treatment with the LHRH antagonist is followed by administration of an analgetic.
33. Use of an LH-RH antagonist according to any one of claims 28 to 32 wherein the short-term induction treatment with the LHRH antagonist is followed by administration of an androgen other than a 17-alpha-alkyl substituted testosterone.
34. Use of an LH-RH antagonist according to any one of claims 28 to 33 wherein the short-term induction treatment with the LHRH antagonist is followed by the combined or separate administration of one or more active agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non- steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha- alkyl substituted testosterone or any combinations thereof.
35. Use of an LH-RH antagonist according to any one of claims 28 to 34 wherein the LHRH antagonist is administered starting in the early to mid follicular phase, preferably on cycle day one to three.
36. Use of an LH-RH antagonist according to any one of claims 28 to 35 wherein the LHRH antagonist is selected from the group consisting of cetrorelix, teverelix, ganirelix, antide, abarelix and D-63153.
37. Use of an LH-RH antagonist according to any one of claims 28 to 36 wherein the LHRH antagonist is administered during the short-term induction treatment for about 4 to 12 weeks at a weekly dose of about 3 to about 10 mg per week.
38. Use of an LH-RH antagonist according to any one of claims 28 to 37 wherein the LHRH antagonist is administered during the short-term induction treatment for about 4 to 12 weeks at a daily dose of about 0.25 mg to about 0.5 mg/day.
39. Use of an LH-RH antagonist according to any one of claims 28 to 38 wherein the LHRH antagonist is administered during the short-term induction treatment for about 4 to 12 weeks at a monthly dose of about 12 to about 40 mg per month.
40. Use of an LH-RH antagonist according to any one of claims 28 to 39 wherein the LHRH antagonist is given for the induction treatment during about 4 to 12 weeks and the treatment is repeated two or three times a year.
41. Use of an LH-RH antagonist and one or more active agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non- steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha- alkyl substituted testosterone, or any combinations thereof, for the preparation of a medicament for the therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and/or fallopian tube obstruction (FTO), whereby the LHRH antagonist is administered in the form of a short-term induction treatment for a period of about 4 to 12 weeks to a patient in need of such treatment, then the administration of the LHRH antagonist is ceased and the one or more active agent selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone, or any combinations thereof, are administered together or separately to the patient.
42. Use of an LH-RH antagonist and one or more active agents according to claim 41 , wherein the LHRH antagonist is administered such that the estrogen serum concentration level is between about 35 pg/ml and about 80 pg/ml, preferably between about 45-75 pg/ml, more preferably about 50-75 pg/ml.
43. Use of an LH-RH antagonist and one or more active agents according according to claims 41 or 42 wherein the short-term induction treatment with the LHRH antagonist is followed by administration of a contraceptive, preferably an oral contraceptive.
44. Use of an LH-RH antagonist and one or more active agents according according according to any one of claims 41 to 43 wherein the short-term induction treatment with the LHRH antagonist is followed by administration of a non- steroidal anti-rheumatic agent.
45. Use of an LH-RH antagonist and one or more active agents according to any one of claims 41 to 44 wherein the short-term induction treatment with the LHRH antagonist is followed by administration of an analgetic.
46. Use of an LH-RH antagonist and one or more active agents according to any one of claims 41 to 45 wherein the short-term induction treatment with the LHRH antagonist is followed by administration of an androgen other than a 17-alpha- alkyl substituted testosterone.
47. Use of an LH-RH antagonist and one or more active agents according to any one of claims 41 to 46 wherein the short-term induction treatment with the LHRH antagonist is followed by the combined or separate administration of one or more active agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone or any combinations thereof.
48. Use of an LH-RH antagonist and one or more active agents according to any one of claims 41 to 47 wherein the LHRH antagonist is administered starting in the early to mid follicular phase, preferably on cycle day one to three.
49. Use of an LH-RH antagonist and one or more active agents according to any one of claims 41 to 48 wherein the LHRH antagonist is selected from the group consisting of cetrorelix, teverelix, ganirelix, antide, abarelix and D-63153.
50. Use of an LH-RH antagonist and one or more active agents according to any one of claims 41 to 49 wherein the LHRH antagonist is administered during the short- term induction treatment for about 4 to 12 weeks at a weekly dose of about 3 to
10 mg per week.
51. Use of an LH-RH antagonist and one or more active agents according to any one of claims 41 to 50 wherein the LHRH antagonist is administered during the short- term induction treatment for about 4 to 12 weeks at a daily dose of about 0.25 mg to 0.5 mg/day.
52. Use of an LH-RH antagonist and one or more active agents according to any one of claims 41 to 51 wherein the LHRH antagonist is administered during the short- term induction treatment for about 4 to 12 weeks at a monthly dose of about 12 to
40 mg per month.
3. Use of an LH-RH antagonist and one or more active agents according to any one of claims 41 to 52 wherein the LHRH antagonist is given for the induction treatment during about 4 to 12 weeks and the treatment is repeated two or three times a year.
PCT/EP2000/009212 1999-09-23 2000-09-20 Method for the therapeutic management of endometriosis and fallopian tube obstruction WO2001021194A2 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
JP2001524618A JP2003509467A (en) 1999-09-23 2000-09-20 Method for treating extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction
BR0014198-4A BR0014198A (en) 1999-09-23 2000-09-20 Process for the therapeutic management of extra-uterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction
HU0202741A HUP0202741A3 (en) 1999-09-23 2000-09-20 Pharmaceutical composition available for the therapeutic management of endometriosis and fallopian tube obstruction and process for its preparation
UA2002043346A UA73956C2 (en) 1999-09-23 2000-09-20 Method for therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction due to extrauterine proliferation of endometrial tissue
AU77792/00A AU769482B2 (en) 1999-09-23 2000-09-20 Method for the therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction
EP00967722A EP1214086A2 (en) 1999-09-23 2000-09-20 Method for the therapeutic management of endometriosis and fallopian tube obstruction
SK375-2002A SK3752002A3 (en) 1999-09-23 2000-09-20 Method for the therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction
PL353244A PL201898B1 (en) 1999-09-23 2000-09-20 Method for the therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction
CA002383510A CA2383510A1 (en) 1999-09-23 2000-09-20 Method for the therapeutic management of extrauterine proliferation of endometreial tissue, chronic pelvic pain and fallopian tube obstruction
IL14818500A IL148185A0 (en) 1999-09-23 2000-09-20 Method for the therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction
MXPA02002436A MXPA02002436A (en) 1999-09-23 2000-09-20 Method for the therapeutic management of endometriosis and fallopian tube obstruction.
NO20021430A NO331198B1 (en) 1999-09-23 2002-03-21 Use of the LHRH antagonist for the manufacture of a drug for therapeutically controlling extrauterine endometrial proliferation, chronic pelvic pain and fallopian tube obstruction
BG106584A BG66128B1 (en) 1999-09-23 2002-04-05 Pharmaceutical composition and use for the therapeutic management of extrauterine proliferation of endometrial tissue
HK03101215.4A HK1049117A1 (en) 1999-09-23 2003-02-18 Method for the therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15547899P 1999-09-23 1999-09-23
US60/155,478 1999-09-23

Publications (2)

Publication Number Publication Date
WO2001021194A2 true WO2001021194A2 (en) 2001-03-29
WO2001021194A3 WO2001021194A3 (en) 2002-03-14

Family

ID=22555601

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/009212 WO2001021194A2 (en) 1999-09-23 2000-09-20 Method for the therapeutic management of endometriosis and fallopian tube obstruction

Country Status (22)

Country Link
EP (1) EP1214086A2 (en)
JP (2) JP2003509467A (en)
KR (1) KR100772852B1 (en)
CN (2) CN1376070A (en)
AU (1) AU769482B2 (en)
BG (1) BG66128B1 (en)
BR (1) BR0014198A (en)
CA (1) CA2383510A1 (en)
HK (1) HK1049117A1 (en)
HU (1) HUP0202741A3 (en)
IL (1) IL148185A0 (en)
MX (1) MXPA02002436A (en)
NO (1) NO331198B1 (en)
NZ (1) NZ534836A (en)
PL (1) PL201898B1 (en)
RU (1) RU2255759C2 (en)
SK (1) SK3752002A3 (en)
TR (1) TR200200738T2 (en)
TW (1) TWI267373B (en)
UA (1) UA73956C2 (en)
WO (1) WO2001021194A2 (en)
ZA (1) ZA200201374B (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003045419A1 (en) * 2001-11-26 2003-06-05 Zentaris Gmbh Injection solution comprising an lhrh antagonist
US7214662B2 (en) 2001-11-27 2007-05-08 Zentaris Gmbh Injectable solution of an LHRH antagonist
WO2010085145A1 (en) * 2009-01-22 2010-07-29 Maatschap Interne Geneeskunde Rijnstate Method for the prophylaxis or treatment of flushing
US8318899B2 (en) 2008-01-24 2012-11-27 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Lytic domain fusion constructs and methods of making and using same
US9492563B2 (en) 2012-10-30 2016-11-15 Esperance Pharmaceuticals, Inc. Antibody/drug conjugates and methods of use
EP3560555A1 (en) * 2018-04-26 2019-10-30 LifeArc A composition for treating one or more estrogen related diseases
US10881659B2 (en) 2013-03-15 2021-01-05 Abbvie Inc. Methods of treating heavy menstrual bleeding
US11690854B2 (en) 2018-04-19 2023-07-04 Abbvie Inc. Methods of treating heavy menstrual bleeding

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997027863A1 (en) * 1996-01-29 1997-08-07 Schering Aktiengesellschaft Combined pharmaceutical preparation containing lhrh-analogous substances and anti-estrogens for treating gynaecological disorders
US5658884A (en) * 1994-07-22 1997-08-19 The Medical College Of Hampton Roads Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens
WO1998055470A1 (en) * 1997-06-05 1998-12-10 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
EP0943336A1 (en) * 1996-09-04 1999-09-22 Dott Research Laboratory Peptide-containing pharmaceutical compositions for oral administration
WO2000055190A1 (en) * 1999-03-17 2000-09-21 Zentaris Ag Novel lhrh antagonists with improved solubility characteristics

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5064939A (en) * 1990-02-06 1991-11-12 The Salk Institute For Biological Studies Cyclic gnrh antagonists
SE9301606D0 (en) * 1993-05-07 1993-05-07 Per-Christer Oden COMPOSITION FOR THE TREATMENT OF IMPAIRED HAIR GROWTH
RU2181598C2 (en) * 1994-07-22 2002-04-27 Дзе Медикал Колледж оф Хэмптон Роудс Recovery of tonic secretion of ovarian estrogen for prolonged therapeutic schemes
DE19513662A1 (en) * 1995-04-08 1996-10-10 Schering Ag Combined pharmaceutical preparation for hormonal contraception

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658884A (en) * 1994-07-22 1997-08-19 The Medical College Of Hampton Roads Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens
WO1997027863A1 (en) * 1996-01-29 1997-08-07 Schering Aktiengesellschaft Combined pharmaceutical preparation containing lhrh-analogous substances and anti-estrogens for treating gynaecological disorders
EP0943336A1 (en) * 1996-09-04 1999-09-22 Dott Research Laboratory Peptide-containing pharmaceutical compositions for oral administration
WO1998055470A1 (en) * 1997-06-05 1998-12-10 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
WO2000055190A1 (en) * 1999-03-17 2000-09-21 Zentaris Ag Novel lhrh antagonists with improved solubility characteristics

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NORMAN P: "Cetrorelix, ASTA Medica AG" CURRENT OPINION IN ONCOLOGIC, ENDOCRINE & METABOLIC INVESTIGATIONAL DRUGS, vol. 2, no. 2, pages 227-248, XP000982761 *
See also references of EP1214086A2 *

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002365504B2 (en) * 2001-11-26 2007-06-28 Zentaris Ivf Gmbh Injection solution comprising an LHRH antagonist
HRP20040587B1 (en) * 2001-11-26 2008-01-31 Zentaris Gmbh Injection solution comprising an lhrh antagonist
CN100404068C (en) * 2001-11-26 2008-07-23 赞塔里斯有限公司 Injection solution comprising an LHRH antagonist
EA010787B1 (en) * 2001-11-26 2008-10-30 Центарис Гмбх Injection solution comprising an lhrh antagonist
WO2003045419A1 (en) * 2001-11-26 2003-06-05 Zentaris Gmbh Injection solution comprising an lhrh antagonist
US7790686B2 (en) 2001-11-27 2010-09-07 Werner Sarlikiotis Injection solution of an LHRH antagonist
US7214662B2 (en) 2001-11-27 2007-05-08 Zentaris Gmbh Injectable solution of an LHRH antagonist
US9255134B2 (en) 2008-01-24 2016-02-09 Esperance Pharmaceuticals, Inc. Lytic domain fusion constructs and methods of making and using same
US8318899B2 (en) 2008-01-24 2012-11-27 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Lytic domain fusion constructs and methods of making and using same
US8546535B2 (en) 2008-01-24 2013-10-01 Esperance Pharmaceuticals, Inc. Lytic domain fusion constructs and methods of making and using same
WO2010085145A1 (en) * 2009-01-22 2010-07-29 Maatschap Interne Geneeskunde Rijnstate Method for the prophylaxis or treatment of flushing
US9492563B2 (en) 2012-10-30 2016-11-15 Esperance Pharmaceuticals, Inc. Antibody/drug conjugates and methods of use
US10233214B2 (en) 2012-10-30 2019-03-19 Esperance Pharmaceuticals, Inc. Antibody/drug conjugates and methods of use
US11344551B2 (en) 2013-03-15 2022-05-31 Abbvie Inc. Methods of treating heavy menstrual bleeding
US10881659B2 (en) 2013-03-15 2021-01-05 Abbvie Inc. Methods of treating heavy menstrual bleeding
US11045470B2 (en) 2013-03-15 2021-06-29 Abbvie Inc. Methods of treating heavy menstrual bleeding
US11707464B2 (en) 2013-03-15 2023-07-25 Abbvie Inc. Methods of treating heavy menstrual bleeding
US11690854B2 (en) 2018-04-19 2023-07-04 Abbvie Inc. Methods of treating heavy menstrual bleeding
WO2019207026A1 (en) * 2018-04-26 2019-10-31 Lifearc A composition for treating one or more estrogen related diseases
EP3560555A1 (en) * 2018-04-26 2019-10-30 LifeArc A composition for treating one or more estrogen related diseases
US11446351B2 (en) 2018-04-26 2022-09-20 Lifearc Composition for treating one or more estrogen related diseases

Also Published As

Publication number Publication date
CA2383510A1 (en) 2001-03-29
CN101045155A (en) 2007-10-03
UA73956C2 (en) 2005-10-17
BG106584A (en) 2003-02-28
BG66128B1 (en) 2011-06-30
EP1214086A2 (en) 2002-06-19
NO331198B1 (en) 2011-10-31
NZ534836A (en) 2007-07-27
KR20020035879A (en) 2002-05-15
HUP0202741A2 (en) 2003-01-28
CN1376070A (en) 2002-10-23
KR100772852B1 (en) 2007-11-02
JP2012051920A (en) 2012-03-15
WO2001021194A3 (en) 2002-03-14
NO20021430L (en) 2002-05-07
HK1049117A1 (en) 2003-05-02
TR200200738T2 (en) 2002-08-21
HUP0202741A3 (en) 2003-12-29
RU2255759C2 (en) 2005-07-10
SK3752002A3 (en) 2003-06-03
IL148185A0 (en) 2002-09-12
AU7779200A (en) 2001-04-24
TWI267373B (en) 2006-12-01
MXPA02002436A (en) 2003-02-12
PL201898B1 (en) 2009-05-29
NO20021430D0 (en) 2002-03-21
ZA200201374B (en) 2002-10-30
PL353244A1 (en) 2003-11-03
AU769482B2 (en) 2004-01-29
JP2003509467A (en) 2003-03-11
BR0014198A (en) 2002-05-21

Similar Documents

Publication Publication Date Title
JP3130048B2 (en) Estrogen addiction treatment
ES2281551T3 (en) METHOD OF PREVENTION OR TREATMENT OF BENIGN GYNECOLOGICAL DISEASES.
JP2012051920A (en) Pharmaceutical composition for treatment of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction, lhrh antagonist for manufacturing drugs to treat the diseases or lhrh antagonist and active agent
Erkkola et al. Role of progestins in contraception
JP5543920B2 (en) Treatment of estrogen-dependent symptoms in premenopausal women
Cheng et al. Medical treatment for uterine myomas
US7666836B2 (en) Method for the therapeutic management of endometriosis
TW577735B (en) Pharmaceutical combined preparation and its use in the treatment of gynaecological disorders
Bedaiwy et al. Aromatase inhibitors prevent the estrogen rise associated with the flare effect of gonadotropins in patients treated with GnRH agonists
JP2012077020A (en) Combination medicine of gestagen and gnrh antagonist
Bergqvist Current drug therapy recommendations for the treatment of endometriosis
BG106442A (en) Mesoprogestins (progesterone receptor modulators) for the treatment and prevention of benign hormone dependent gynecological disorders
BG63363B1 (en) THE USE OF GnRH ANTAGONIST FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF GONADOSTEROID-DEPENDENT DISEASES
JP3925688B2 (en) Pharmaceutical formulation for treating side effects during and / or after GnRHa treatment
BR112020021565A2 (en) COMPOSITION FOR TREATING ONE OR MORE ESTROGEN-RELATED DISEASES
Patel Response of the Uterus to Medication: Hysteroscopic Implications
Patel 6 Hysteroscopic Implications
US20020002153A1 (en) Pharmaceutical preparations for treating side effects during and/or after gnrha therapy
PL188998B1 (en) The use of antagonists lh-rh (a material that releases the luteinizing hormone) as a diagnose medium

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BG BR BY CA CN CZ DZ EE GE HR HU ID IL IN IS JP KG KR KZ LT LV MK MX NO NZ PL RO RU SG SI SK TR UA US UZ YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 148185

Country of ref document: IL

Ref document number: IN/PCT/2002/231/KOL

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2002/01374

Country of ref document: ZA

Ref document number: 200201374

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2000967722

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 517373

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 77792/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/002436

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2383510

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PV2002-908

Country of ref document: CZ

AK Designated states

Kind code of ref document: A3

Designated state(s): AU BG BR BY CA CN CZ DZ EE GE HR HU ID IL IN IS JP KG KR KZ LT LV MK MX NO NZ PL RO RU SG SI SK TR UA US UZ YU ZA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 3752002

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 008131961

Country of ref document: CN

Ref document number: 1020027003740

Country of ref document: KR

Ref document number: 2002/00738

Country of ref document: TR

ENP Entry into the national phase

Ref document number: 2001 524618

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2000 106584

Country of ref document: BG

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2002 2002111000

Country of ref document: RU

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1020027003740

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2000967722

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV2002-908

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 77792/00

Country of ref document: AU